PTGS2 and neoplasm: In addition, all drug treated mice including platycodin D 50 mg/kg showed significant (P < 0.01 or P < 0.05) increases of caspase-3 and PARP immunoreactivities in the tumor mass and decreases of COX-2-immunolabeled cells as compared with tumor-bearing control mice, respectively (Table 4, Figure 8).